FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000702525> ?p ?o ?g. }

• W2000702525 endingPage "71" @default.
• W2000702525 startingPage "64" @default.
• W2000702525 abstract "Summary. In a prospective study, we evaluated the role of early treatment with ganciclovir of human cytomegalvirus (HCMV) pp65‐antigenaemia, as well as the risk factors related to the infection in 48 paediatric patients given an allogeneic bone marrow transplantation (BMT). HCMV infection occurred in 24 children, the overall actuarial risk of infection at 120 d being 51%. Development of acute graft‐versus‐host disease (GVHD), steroid therapy and serological status of both recipient and donor were the most powerful predictors of HCMV infection, none of the six seronegative patient/donor pairs developing HCMV infection. Considering only the seropositive recipients and patients given a seropositive marrow (42 cases), the actuarial risk of developing HCMV antigenaemia in patients with acute GVHD was 76% v 27% in those with or without GVHD (P < 0.005) and 79% v 15% respectively in patients who did or did not receive steroid therapy (P < 0.001). HCMV disease developed in 5/24 children with pp65‐antigen‐aemia, which was detected before diagnosis in all cases but one. All patients with pp65‐positive cells were treated with ganciclovir at a dose of 5 mg/kg twice daily for 14d. In patients without acute GVHD no maintenance therapy was adminis‐tered, whereas children with active acute GVHD were given additional therapy with ganciclovir at a dose of 5 mg/kg/d for 14d. Ganciclovir produced complete clearing of viraemia and antigenaemia, with some patients presenting recurrences of antigenaemia, which were treated according to the above‐mentioned schedule. Likewise, HCMV disease completely resolved after treatment with ganciclovir and no patients died from HCMV‐related interstitial pneumonia. Our results suggest that an early short‐term therapy with ganciclovir after demonstration of antigenaemia can be effective in reducing or abolishing HCMV‐related mortality. This approach elim‐inates the use of ganciclovir in patients not presenting HCMV reactivation and therefore not benefiting from therapy. The administration of ganciclovir limited to the period needed to obtain antigenaemia clearance could also have the advantage of reducing myelotoxicity." @default.
• W2000702525 created "2016-06-24" @default.
• W2000702525 creator A5022712318 @default.
• W2000702525 creator A5050104358 @default.
• W2000702525 creator A5050682361 @default.
• W2000702525 creator A5058693120 @default.
• W2000702525 creator A5061275872 @default.
• W2000702525 creator A5063691573 @default.
• W2000702525 creator A5065063837 @default.
• W2000702525 creator A5069668709 @default.
• W2000702525 date "1994-09-01" @default.
• W2000702525 modified "2023-10-03" @default.
• W2000702525 title "Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenaemaia on Patients' outcome" @default.
• W2000702525 cites W144116704 @default.
• W2000702525 cites W1515011628 @default.
• W2000702525 cites W1530764705 @default.
• W2000702525 cites W1948248797 @default.
• W2000702525 cites W1963969155 @default.
• W2000702525 cites W1982044703 @default.
• W2000702525 cites W1982229907 @default.
• W2000702525 cites W1986693381 @default.
• W2000702525 cites W2001394429 @default.
• W2000702525 cites W2012005476 @default.
• W2000702525 cites W2013103929 @default.
• W2000702525 cites W2034740985 @default.
• W2000702525 cites W2037498951 @default.
• W2000702525 cites W2048680139 @default.
• W2000702525 cites W2053278212 @default.
• W2000702525 cites W2077824147 @default.
• W2000702525 cites W2107757755 @default.
• W2000702525 cites W2110106448 @default.
• W2000702525 cites W211436638 @default.
• W2000702525 cites W2118597625 @default.
• W2000702525 cites W2125385656 @default.
• W2000702525 cites W2132559146 @default.
• W2000702525 cites W2157651001 @default.
• W2000702525 cites W2171889269 @default.
• W2000702525 cites W2315317361 @default.
• W2000702525 cites W2315851568 @default.
• W2000702525 cites W2338358489 @default.
• W2000702525 cites W2340978599 @default.
• W2000702525 cites W4242511899 @default.
• W2000702525 doi "https://doi.org/10.1111/j.1365-2141.1994.tb04978.x" @default.
• W2000702525 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7803258" @default.
• W2000702525 hasPublicationYear "1994" @default.
• W2000702525 type Work @default.
• W2000702525 sameAs 2000702525 @default.
• W2000702525 citedByCount "72" @default.
• W2000702525 countsByYear W20007025252012 @default.
• W2000702525 countsByYear W20007025252013 @default.
• W2000702525 countsByYear W20007025252015 @default.
• W2000702525 countsByYear W20007025252016 @default.
• W2000702525 countsByYear W20007025252018 @default.
• W2000702525 countsByYear W20007025252020 @default.
• W2000702525 crossrefType "journal-article" @default.
• W2000702525 hasAuthorship W2000702525A5022712318 @default.
• W2000702525 hasAuthorship W2000702525A5050104358 @default.
• W2000702525 hasAuthorship W2000702525A5050682361 @default.
• W2000702525 hasAuthorship W2000702525A5058693120 @default.
• W2000702525 hasAuthorship W2000702525A5061275872 @default.
• W2000702525 hasAuthorship W2000702525A5063691573 @default.
• W2000702525 hasAuthorship W2000702525A5065063837 @default.
• W2000702525 hasAuthorship W2000702525A5069668709 @default.
• W2000702525 hasConcept C126322002 @default.
• W2000702525 hasConcept C159654299 @default.
• W2000702525 hasConcept C203014093 @default.
• W2000702525 hasConcept C2522874641 @default.
• W2000702525 hasConcept C2776409557 @default.
• W2000702525 hasConcept C2776724271 @default.
• W2000702525 hasConcept C2777662283 @default.
• W2000702525 hasConcept C2777732132 @default.
• W2000702525 hasConcept C2777965375 @default.
• W2000702525 hasConcept C2779134260 @default.
• W2000702525 hasConcept C2779820661 @default.
• W2000702525 hasConcept C2780007613 @default.
• W2000702525 hasConcept C2780727368 @default.
• W2000702525 hasConcept C2911091166 @default.
• W2000702525 hasConcept C45189115 @default.
• W2000702525 hasConcept C71924100 @default.
• W2000702525 hasConcept C90924648 @default.
• W2000702525 hasConceptScore W2000702525C126322002 @default.
• W2000702525 hasConceptScore W2000702525C159654299 @default.
• W2000702525 hasConceptScore W2000702525C203014093 @default.
• W2000702525 hasConceptScore W2000702525C2522874641 @default.
• W2000702525 hasConceptScore W2000702525C2776409557 @default.
• W2000702525 hasConceptScore W2000702525C2776724271 @default.
• W2000702525 hasConceptScore W2000702525C2777662283 @default.
• W2000702525 hasConceptScore W2000702525C2777732132 @default.
• W2000702525 hasConceptScore W2000702525C2777965375 @default.
• W2000702525 hasConceptScore W2000702525C2779134260 @default.
• W2000702525 hasConceptScore W2000702525C2779820661 @default.
• W2000702525 hasConceptScore W2000702525C2780007613 @default.
• W2000702525 hasConceptScore W2000702525C2780727368 @default.
• W2000702525 hasConceptScore W2000702525C2911091166 @default.
• W2000702525 hasConceptScore W2000702525C45189115 @default.
• W2000702525 hasConceptScore W2000702525C71924100 @default.
• W2000702525 hasConceptScore W2000702525C90924648 @default.
• W2000702525 hasIssue "1" @default.

• next